Literature DB >> 21793097

Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday.

Robert J Constantine1, Susan Jentz, Michael Bengtson, Marie McPherson, Ross Andel, Mary Beth Jones.   

Abstract

PURPOSE: This study aims the following: (i) to describe the exposure to antipsychotic medications over a 4-year period experienced by a cohort of children who initiated antipsychotic treatment before their sixth birthday; and (ii) to identify variables associated with the risk of antipsychotic exposure.
METHODS: Children were identified who initiated an index episode of antipsychotic treatment before their sixth birthday in Florida's fee for service Medicaid program. With the use of claims data, the medication utilization of these children was tracked during the year before and the 4 years following the start of their index episodes (pre-index and four post-index periods). Generalized estimating equations were used to identify variables associated with the risk of additional days of antipsychotic exposure.
RESULTS: Five hundred twenty-eight children were included in the cohort. The mean total number of days of exposure was 821.9 (± 431.9), representing 56.3% of all days during the four post-index periods. The mean days of exposure to combinations of antipsychotics and other classes of psychotherapeutic medications were 623.8 ± 447.6 days. Children with primary diagnoses of pervasive developmental disorders and affective disorders were at greater risk of additional days of exposure than children with attention deficit/hyperactivity disorder. Exposure tended to be greater among children with indicators of clinical complexity including the presence of secondary diagnoses and the use of other classes of psychotherapeutic medications in addition to antipsychotics.
CONCLUSIONS: Exposure to antipsychotic mediations was extensive. Although these children may have had complex and severe problems, additional research is urgently needed on the benefits and risks of long-term antipsychotic exposure among very young children.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793097     DOI: 10.1002/pds.2189

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

2.  Analysis of pediatric clinical drug trials for neuropsychiatric conditions.

Authors:  Srinivas Murthy; Kenneth D Mandl; Florence Bourgeois
Journal:  Pediatrics       Date:  2013-05-06       Impact factor: 7.124

3.  Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.

Authors:  Yu-Jung Wei; Xinyue Liu; Nikhil Rao; Marie McPherson; Mary Beth Jones; Regina Bussing; Almut G Winterstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-14       Impact factor: 2.576

Review 4.  Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications.

Authors:  Michael L Birnbaum; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; John M Kane; Christoph U Correll
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

5.  Psychotropic drug use among preschool children in the Medicaid program from 36 states.

Authors:  Lauren D Garfield; Derek S Brown; Benjamin T Allaire; Raven E Ross; Ginger E Nicol; Ramesh Raghavan
Journal:  Am J Public Health       Date:  2015-01-20       Impact factor: 9.308

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.